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Abstract
Previous analysis of the Cerberus like 2 knockout (Cerl22/2) mouse revealed a significant mortality during the first day after
birth, mostly due to cardiac defects apparently associated with randomization of the left-right axis. We have however,
identified Cerl2-associated cardiac defects, particularly a large increase in the left ventricular myocardial wall in neonates
that cannot be explained by laterality abnormalities. Therefore, in order to access the endogenous role of Cerl2 in
cardiogenesis, we analyzed the embryonic and neonatal hearts of Cerl2 null mutants that did not display a laterality
phenotype. Neonatal mutants obtained from the compound mouse line Cer22/2::Mlc1v-nLacZ24+, in which the pulmonary
ventricle is genetically marked, revealed a massive enlargement of the ventricular myocardium in animals without laterality
defects. Echocardiography analysis in Cerl22/2 neonates showed a left ventricular systolic dysfunction that is incompatible
with a long lifespan. We uncovered that the increased ventricular muscle observed in Cerl22/2 mice is caused by a high
cardiomyocyte mitotic index in the compact myocardium which is mainly associated with increased Ccnd1 expression levels
in the left ventricle at embryonic day (E) 13. Interestingly, at this stage we found augmented left ventricular expression of
Cerl2 levels when compared with the right ventricle, which may elucidate the regionalized contribution of Cerl2 to the left
ventricular muscle formation. Importantly, we observed an increase of phosphorylated Smad2 (pSmad2) levels in embryonic
(E13) and neonatal hearts indicating a prolonged TGFbs/Nodal-signaling activation. Concomitantly, we detected an increase
of Baf60c levels, but only in Cerl22/2 embryonic hearts. These results indicate that independently of its well-known role in
left-right axis establishment Cerl2 plays an important role during heart development in the mouse, mediating Baf60c levels
by exerting an important control of the TGFbs/Nodal-signaling pathway.
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Introduction
The heart is the first organ to be formed to allow the efficient
supply of the increasing nutritional requirements of the growing
embryo [1]. A series of processes orchestrated by a complex
genetic network and interplay of the diverse cardiac cell lineages is
essential for a successful cardiogenesis [2]. Subtle perturbations
during heart formation usually lead to congenital heart defects
(CHD) [3], which are the most common congenital malformations
worldwide [4].
In mice, the heart starts to be formed at gastrulation with the
formation of the cardiac crescent at the anterior side of the embryo
[5], which contributes to the heart primordium or first heart field
(FHF) [6]. Cells from FHF will mainly give rise to the left ventricle
(LV) [1]. Later, another region can be identified, the secondary
heart field (SHF) that will mainly contribute to the right ventricle
(RV) and outflow tract (OFT) [7]. The heart primordium region
fuses at the embryonic midline to form a primitive heart tube [8].
In this primitive tubular phase, the heart loops to the right side of
the embryo under the control of the signals that regulate left–right
axis (L/R) [9]. After cardiac looping, two myocardial layers
compose the primitive heart. The trabecular layer is a bundle of
cardiomyocytes outlined by endocardial cells that project across
the lumen of the ventricular chamber [10], and the compact layer
is an organized multilayer that comprises the outmost ventricular
region [11]. The cardiomyocytes that compose the compact layer
have high proliferative and low differentiation capacities and the
reverse is found in trabeculae. As development proceeds, the heart
expands towards a four-chambered organ and the atrio-ventric-
ular septation is established simultaneously with the correct
alignment between arteries and their respective ventricles. This
allows the development of the conducting and circulatory systems
[12]. At the cellular level, the cardiomyocytes proliferate regulated
by cyclins and cyclin-dependent kinase (CDKs) [13,14] reaching
two distinct high rates of DNA synthesis. The first occurs around
midgestation (E12.5) and is associated with increased cardiomy-
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ocyte proliferation [15]. Later, in the first days after birth (P3–P4),
a second peak of DNA synthesis is observed which ultimately
results in binucleated cardiomyocytes [16]. Nonetheless, recent
studies point to continued DNA synthesis and therefore to
neomyocardialization potential in adult hearts [17,18]. On the
other hand cardiomyocyte differentiation occurs early in heart
morphogenesis and persists until the first weeks of birth [19]. Thus
the balance between cellular proliferation and differentiation
during heart formation is crucial to provide the progressive
thickening and maturation of the cardiac myoarchitecture [20].
Cerberus like 2 (Cerl2) is a member of the Cer/Dan family, and
has been shown to antagonize signals from the Transforming
Growth Factor (TGF) type b superfamily [21]. The secreted
protein Cerl2 binds to Nodal and contributes to asymmetric
initiation of the left-right (L/R) axis [21,22]. Accordingly, Cerl2
knockout (Cerl22/2) mice display L/R axis randomized and a
significant mortality rate within a few hours after birth, mostly due
to cardiac defects [21]. In addition, it has been reported that
animals with laterality defects (LD) frequently have impaired
cardiac function correlated with cardiac malformations [23], and a
high mortality rate in mouse and humans [24,25].
In this study we investigated the consequences of Cerl2 loss-of-
function in heart development, independent of the influence of LD
on cardiac structure and function. We analyzed exclusively
animals that did not show LD. Besides, emerging data has
elucidated the role of Cerl-1, another member of Cer/Dan family,
for cardiogenesis initiation, as reported in Xenopus [26], chicken
[27] and in mouse embryonic stem cells [28,29].
Here, we demonstrate that enlargement of the ventricular
myocardial walls in Cerl2 null mutants without LD is caused by
cardiomyocyte hyperplasia possibly due to increased expression
levels of Ccnd1 at midgestation. Moreover, these animals showed
impaired expression of cardiac genes during heart formation and
reduced systolic function in early neonatal life. We also described
that Cerl2 expression levels are augmented in the LV at E13.5,
indicating a possible preponderant function of Cerl2 in this
ventricle during cardiogenesis. In accordance with these observa-
tions, we detected in Cerl22/2 embryonic hearts an increase of
phosphorylated Smad2 (pSmad2) levels, a mediator of TGFbs/
Nodal-signaling and of Baf60c levels, a subunit of SWI/SNF
chromatin remodeling complex. Taken together, we conclude that
Cerl2 emerges as an essential factor in the control of the TGFbs/
Nodal-signaling acting as a modulator of the SWI/SNF-like BAF
chromatin remodeling complex that takes place during embryonic
cardiogenesis being this role essential for proper heart formation.
Methods
Ethics Statement
The studies involving animal experiments are in accordance to
the ethical issues for clinical research and EU guidelines for animal
research. All animal work performed in this study was conducted
in compliance with the Portuguese law and approved by the
Consultive Commission of the Veterinary Agency from Portu-
guese Ministry of Agriculture (Directive 2010/63/EU of the
European Parliament), the Agency responsible for issuing approval
for experimental animal studies, following the EU guidelines for
animal research and welfare.
Mice
The mouse lines used in this work, wild type, Mlc1v-nLacZ24
and Cerl22/2 (129Sv background) were maintained at 20uC 62uC
in a 12 hour light-dark cycle. Noon of the day of detection of the
vaginal plug was considered embryonic stage E0.5. Pregnant
females were euthanized by cervical dislocation. The uterine horns
were immediately removed and the embryos were dissected. After
the echocardiography recordings, the deeply anesthetized neonatal
mice (4% isoflurane mixed with 1L/minutes 100% Oxygen) were
sacrificed by injection in the LV with a cardioplegic solution (1.5%
KCl) to induce cardiac arrest.
Sample Preparation
For paraffin and frozen tissue embedding the embryos and
neonatal hearts were fixed in 4% paraformaldehyde (PFA)
overnight (O/N). For qRT-PCR and Western Blot the whole
embryos and isolated hearts were frozen directly in dry ice and
stored at 280uC.
Histology
The hearts were sectioned transversally in 10 and 5 mm
thickness (embryos and neonatal hearts respectively). Haematox-
ylin and Eosin (H&E) and Masson-trichrome (TRI) staining were
performed on paraffin-embedded sections, according to standard
practices. To measure the wall thickness in embryonic hearts,
three serial sections were chosen, having as guideline the four-
chambers and the central conduction system [11]. Five parts per
section were arbitrarily chosen for each mouse. The proportion of
the compact and trabecular layers to the heart size was the ratio
between their respective lengths and the longest diameter of the
ventricle [30]. In neonatal hearts, five sections at the level of mid-
papillary muscle were chosen to measure the anterior, lateral and
posterior LV and RV walls, and the IVS as well. The data was
normalized by the body weight. A blinded observer to mouse
genotypes conducted the data analysis. AxioVision Image Soft-
ware (Zeiss Company) was used for measurements.
b-Galactosidase Staining
b-Galactosidase staining was performed in neonatal hearts
according to standard procedures [31]. To perform morphometric
analysis, the sections at mid-papillary muscle level were chosen
and indexed to body weight.
Immunohistochemistry
The immunohistochemistry (IHC) protocol was performed
according standard procedures (Abcam protocol: http://www.
abcam.com). Antibody sources are listed in Table S1.
Cell counting and measurements
The quantification of proliferating cardiomyocytes in the
compact layer of embryonic hearts was performed on 9 fields
per ventricle (three fields per section) divided by the total of
cardiomyocytes counted in each ventricle (n = 4–5 per genotype).
The mitotic index to neonatal hearts was obtained from 9 fields of
the right and left ventricular wall (AW, LW, and PW) and IVS
divided by the total of cardiomyocytes counted per ventricular wall
(n = 4–5 per genotype). The images were obtained using confocal
microscopy (LSM 710, Zeiss Company; under 63X or 40X
magnification for embryonic hearts, or fetal and neonatal hearts,
respectively). Random regions of the compact layer were selected
and fixed sizes of the fields were determined using Adobe
Photoshop CS4 software to count the cardiomyocytes. The
guidelines used to choose the sections were the same used to
measure the myocardial thickness that were described in the
Histology section of the methods.
The cardiomyocyte area was assessed from the LVAW, LVPW
and IVS (6–8 sections per heart, n = 3), using optical sectioning
with an Apotome microscope (Axio Imager Z2 Fluorescence, Zeiss
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Company; 63X magnification). We obtained the relative cell area
through delineation of 100 cardiomyocytes for each mouse using
Zen software (Zeiss Company).
The quantification of pSmad2 immunofluorescence signal in the
cardiomyocytes present in the compact layer at E13 was
conducted using ImageJ software and adapted from Dr. T.
Nakamura Lab. protocol [32]. Briefly, we randomly selected nine
fields per each ventricle using three sections per sample. In each
image, the background fluorescence level was assessed by
averaging background signals and was subtracted from the
fluorescence in compact myocardium. Six randomly chosen
fluorescent cardiomyocyte nuclei were marked manually per field,
and then fluorescence values were obtained automatically.
A single observer blinded to mouse genotypes performed data
analysis.
Western blot
For total protein extracts, embryonic and neonatal hearts were
lysed using protein extraction buffer (10 mM Tris HCl pH 7.5,
150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40 and 10%
Glycerol) supplemented with complete protease inhibitor cocktail
(Roche) and a phosphatase inhibitor (CalbiochemH). Following
extraction, total proteins were separated by SDS-PAGE poly-
acrylamide gel (8%), transferred onto Immun-Blot PVDF mem-
brane (Biorad Laboratories), blotted with primary antibodies, and
then incubated with horseradish peroxidase-conjugated secondary
antibodies. Western blots (WB) were developed with Immun–Star
WesternC Chemiluminescence Kit (Bio-Rad) and visualized using
Quemi-Doc Imaging system (Bio-Rad). Densitometry measure-
ments of relative protein quantities were determined by Image Lab
4.0 software (Bio-Rad). Antibody sources are listed in Table S1.
RNA extraction and qRT-PCR
Total RNA was extracted from embryonic and neonatal hearts
using TRI ReagentH (Sigma-Aldrich). RNA samples were treated
with RNAse free DNase kit (Ambion) prior to reverse transcrip-
tion. RNA quantity, quality and integrity were evaluated using a
spectrophotometer (Nano Drop, Thermo Scientific) and Experi-
onTM (Bio-Rad). First strand cDNA was synthesized using 0,5 mg
of RNA, according to the manufacturer’s guidelines. Briefly, RNA
was primed with oligo(dT) and the first strand was synthesized
using SuperscriptII (Invitrogen). Triplicate qRT-PCR reactions
were performed. Negative controls to assess genomic contamina-
tion were achieved for each genotype, without reverse transcrip-
tase. Non-template control (without RNA template) also was
included in the reaction as a negative control, which resulted in no
detectable amplification product. Relative quantification was
performed according to the 22DDCt method [33], and normalized
to GAPDH and HPRT1 as reference genes. Primer sequences for
qRT-PCR are available upon request.
Echocardiography
Neonatal mice were submitted to high-resolution echocardiog-
raphy VEVO 2010 (VisualSonics, Toronto, Canada) using a 40-
MHz high-frequency linear transducer. Mice were anesthetized
with 0.8–1% Isoflurane mixed with 1 L/min 100% Oxigen
delivered by a facemask during the procedure, using the minimum
concentration required to suppress spontaneous body movements.
Prewarmed gel was used as an ultrasound-coupling medium. Body
temperature and heart rate could not be monitored due to small
size of the animals. Two dimensional (B-) mode and spectral Color
Doppler recordings were saved for subsequent analysis. Each
ultrasound exam took 5–7 minutes per mouse (from the onset of
anesthesia to the end of echocardiography procedures). The
measures were obtained from three and five successive cardiac
cycles (B-mode and Color Doppler, respectively), and the data was
averaged. A blinded observer conducted the echocardiographic
measures.
The heart rate (HR) was determined from 4–5 averaged
wavelengths from aortic flow. From spectral Color Doppler
tracing we obtained the aortic and pulmonary peak velocities
(suprasternal and parasternal long axis views, respectively). The
LVM (mg) was calculated according the Area-Length (AL)
formula:
LVM ALð Þ~1:05 5
6




The factor 1.05 represents the myocardium density [34]; (A1)
and (A2) means epicardial and endocardial border obtained
through B-mode in parasternal short axis view (PSAX) at the end
of systole; (L), the major length was obtained in parasternal long
axis view (PLAX) from apex to aortic annulus, and (T) denotes the
mean wall thickness calculated from (A1) and (A2).
The Stroke Volume (SV) is a product of the circular vessel area
pr2~0:785|D2
 
where (D) is a diameter of aortic annulus
obtained from PLAX, and the time velocity integral (TVI) was
obtained from aortic flow.
SV~0:785|D2|TVI
The Cardiac output (CO) is a product of the SV and the HR.
The LVM index (mg/g) and the CO index (ml/min/g) were
calculated by normalization with the body weight.
Statistical Analysis
The data obtained from all analyses was statically analyzed
using GraphPad PRISM 5 software. Statistical differences were
determined by 2–tailed, unpaired Student t test. Probability values
of P,0.05 were considered significant. All results are represented
as mean 6SEM.
Results and Discussion
Cerl22/2 neonates display left ventricular hypertrophy with
increased left ventricular mass and severe cardiac dysfunction.
Figure 1. Increased compact myocardium and systolic dysfunction in Cerl22/2 neonates is independent of the LD phenotype. (A, B
and D) Transverse sections (5 mm) of hearts stained with H&E (A and B) and b-Galactosidase staining counter-stained with Eosin (D). (A9 and B9) Note
the numbers of cardiomyocytes per field (100X). (C and E) Quantitative measures of myocardial thickness in the compact layer indicate increased LV
and IVS thickness (n = 5 and n=4, respectively). (F–K) Echocardiographic analysis (n = 5–6 for WT and n= 7 for Cerl22/2). (F) Represents the Ao peak
velocity by Colour Doppler. (G) Represents the PSAX in B-mode view. (H) LVM index (mg/g) is increased in null mutants; (I) Heart Rate (bpm, beats per
minute), (J) Ao peak velocity (mm/s) and (K) CO index (ml/min/g) are reduced in Cerl22/2 neonates. Ao, aorta artery; AW, anterior wall; CO, cardiac
output; IVS, interventricular septum; LW, lateral wall; LV, left ventricle; LVM, left ventricular mass; PW, posterior wall and RV, right ventricle. Scale bars:
200 mm. * P,0.05 and ** P,0.01.
doi:10.1371/journal.pone.0102716.g001
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It has been extensively reported that laterality defects are
characterized by failure in the L/R axis establishment followed by
randomized positioning of the asymmetrical visceral organs [23].
In order to identify the animals without LD, we started our
analysis by performing echocardiographic examination of Cerl22/
2 neonatal hearts, and complemented it with observation of the
relative positions of the heart and arteries, lung lobulation, liver
and stomach disposition within the body. In contrast to the wild
type (WT) controls, a third of Cerl22/2 neonates die immediately
after birth and a few more until the time of weaning (data not
shown). From the 52 living neonates analyzed, 38 (73%) did not
display LD. These hearts were sectioned to further histomor-
phometry of the anterior (AW), lateral (LW) and posterior wall
(PW) of the LV and RV. The interventricular septum (IVS) was
also measured.
Histological analysis showed an enlarged LV myocardium and
IVS in the Cerl22/2 neonates (Fig. 1A and 1B). Additionally, at
higher magnifications we observed an increased cardiomyocyte
number as seen by higher numbers of nuclei by section (Fig. 1A9
and 1B9). Histomorphometric evaluation revealed an increased
thickening of the walls that constitute the LV myocardium and the
IVS (Fig. 1C). Despite no statistical significant differences, there
was a tendency toward the increase of the RV wall thickness in
Cerl2 null mutants when compared to WT controls.
In order to validate that the increased LV and IVS myocardial
walls found in Cerl22/2 neonates is not related with the cardiac-
associated laterality phenotype, we crossed our null mutant mice
with the Mlc1v-nlacZ-24 transgenic mouse line. This transgenic line
contains a reporter transgene that mimics Fgf10 expression in the
developing heart by expressing b-galactosidase in the RV and
OFT [35]. The neonates obtained by crossing the compound
Cerl2+/2:: Mlc1v-nlacZ-24+ were analyzed by combining the
analysis of visceral organ arrangement with ventricle location of
b-galactosidase staining. By using this method we were able to
identify the animals that did not display cardiac LD, that as shown
in Figure 1D, have the RV marked by b-galactosidade staining as
in transgenic Mlc1v-nlacZ-24+. We analyzed only the ventricle
walls of Cerl22/2: Mlc1v-nlacZ-24+ animals without LD, which
were about half of the living neonates (6/11). Histomorphometry
analysis in the compound animals (Fig. 1E), confirmed that the LV
(AW and LW) and IVS myocardium is hypertrophic in the Cerl2
mutants in the absence of LD. Moreover, in these compound
animals the RVPW was significantly and the RVAW was
tendentiously increased when compared with the control. Alto-
gether these data suggest that in absence of Cerl2 the neonates
showed evident ventricular hypertrophy, and this is independent of
the LD phenotype.
To complement the hypertrophic phenotype study, we evalu-
ated the left ventricular mass (LVM) and the cardiac function
through non-invasive transthoracic echocardiography in neonatal
mice (Fig. 1F–K). According to our analysis the LVM index, a
useful parameter to detect hypertrophy, is increased in Cerl22/2
neonatal hearts (Fig. 1H). The wet heart weight/body weight
ratio, which is also indicative of hypertrophy, has been described
to be imprecise in smaller mice [36]. This could account for the
fact that we did not find significant differences in this parameter
when comparing with WT (Table S2). We determined the heart
Figure 2. Progressive increase of compact myocardium is
already detected in Cerl22/2 embryos. (A–B and D–E) Transverse
sections (10 mm) stained with H&E at E13 and E15 respectively (5X). (C
and F) Quantitative measurements of myocardial thickness in the
compact and trabecular layers are depicted (E13, n = 4 and E15, n = 5).
Note the progressive increase of the compact myocardium after the
compaction process. LV, left ventricle and RV, right ventricle. A9–A99 and
B9–B99; 20X, and D9 and E9, 10X. * P,0.05.
doi:10.1371/journal.pone.0102716.g002
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rate (HR) using the time interval between four-five successive
waveforms on Color Doppler mode tracings of the aortic (Ao) peak
velocity. According to our data, Cerl22/2 neonatal mice have a
decreased HR (Fig. 1I). Furthermore, the LV function was also
affected as suggested by the decreased ascending aorta artery peak
velocity in Cerl2 null mutants (Fig. 1F and 1J). In addition, the
pulmonary systolic performance was also analyzed by the
pulmonary (PA) peak velocity [37], and no significant differences
were found in Cerl22/2 neonates (Table S2). The cardiac output
index (COi), a parameter which indicates the systolic function [34]
was calculated to the LV and a reduced COi was found in Cerl2
mutants (Fig. 1K). Although these results demonstrate that the
Cerl2 null neonates display abnormal cardiac physiology, the basis
for systolic dysfunction in Cerl22/2 is unknown so far. However,
these animals exhibit an interesting postnatal phenotype, which
may suggest that in absence of Cerl2, the neonatal mutants do not
properly respond to increased hemodynamic workload required to
switch from pre- to postnatal phase. Taken together, the data
presented here indicates that the LV hypertrophy observed in
Cerl22/2 is associated with impaired left ventricular systolic
function.
The thickening of ventricular myocardial wall in Cerl22/2
mice starts to develop already during embryonic heart
development
In order to understand if the increase of the LV walls and IVS
found in neonatal hearts originates during prenatal stages, we
analyzed the trabecular and compact layers in embryonic and fetal
hearts, which are crucial to increased thickness of the heart during
cardiogenesis. The trabeculae become compacted towards the
compact layer around at E14 consequently at E16 onwards the
myocardium is mainly constituted by compact layer [20,38].
Therefore, we decided to investigate the myocardial growth before
and after the compaction process (E13.25 and E15.25, respective-
ly). According to a previous report, the RV and LV show no
differences in the myocardial thickness before this process [20]
and, histomorphometric analysis showed that at E13–13.25, the
compact layer in both ventricles of Cerl22/2 mutant also seems not
Figure 3. Cerl22/2 animals display increase in the ventricular mitotic index. (A and B) Corresponds to merged images at E13 of MF20
(green), pH3 (red) and DAPI (blue). (A9 and B9) MF20 and pH3; (A99 and B99) pH3 and DAPI (63X). White arrowheads indicate proliferating
cardiomyocytes in the compact myocardium. (C–F) Proliferating cardiomyocytes observed in different stages of the heart development. (C) E13–
13.25, n = 4; (D) E15–E15.25, n = 5; (E) P0 hearts, n = 5. (F) The timeline of mitotic cardiomyocytes in the LV. aw, anterior wall; IVS, interventricular
septum; LW, lateral wall; LV, left ventricle; PW, posterior wall and RV, right ventricle. * P,0.05 and ** P,0.01.
doi:10.1371/journal.pone.0102716.g003
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to differ from WT (Fig. 2C). In contrast, the trabecular layer of the
LV is larger in Cerl22/2 (Fig. 2A–A99, B–B99 and C), and despite
the trend no statistical difference was found in the right ventricular
trabecular layer when comparing with WT (Fig. 2A–A9, 2B–B9
and 2C). These results may indicate that increased LV trabecular
expansion could lead to an increase of the compact layer during
the compaction process in Cerl22/2 embryonic hearts.
At the second time point studied, at E15–15.25, Cerl22/2 hearts
showed a thicker LV compact layer (Fig. 2D–D9, 2E–E9 and 2F).
However, the LV trabecular length was now similar to WT. The
thickness of the right ventricular compact layer of Cerl22/2 at this
stage did not differ from WT. In contrast, Cerl22/2 showed
seemingly an augmentation of the right ventricular trabeculation
(Fig. 2F), however it was not sufficient to generate a statistically
significant enlarged RV myocardium. The hypertrabeculation
usually is associated with non-compaction in the ventricles,
resulting in a thin compact layer [39,40]. Despite the increased
trabeculae expansion observed in the RV of Cerl22/2, thinner RV
myocardial walls were not observed. This shift from thickened LV
trabecular layer at E13 in Cerl22/2 to thickened compact layer at
E15 may be likely related with the compaction process.
Mitotic cardiomyocytes are increased in compact
myocardium of Cerl22/2 embryonic and neonatal hearts
To investigate the cellular phenotype underlying the hypertro-
phic cardiomyopathy, we evaluated the number of mitotic
cardiomyocytes in Cerl22/2 embryos (E13–13.25), fetuses (E15–
15.25) and neonates (P0), which during embryonic mouse
development, are singly nucleated [41]. To that end, we
immuno-labeled cardiomyocytes with heavy chain cardiac myosin
(MF-20) or sarcomeric a-actinin antibodies and co-labeled with
the mitotic marker phospho-Histone H3 (pH3) antibody. This
allowed us to calculate the mitotic index as the ratio between
proliferating cardiomyocytes and the total number of cardiomy-
ocytes.
At E12.5, the first peak of DNA synthesis is normally observed
in cardiomyocytes [42]. At E13–13.25, we observed in the LV of
the compact myocardium an elevated cardiomyocyte proliferation
(Fig. 3A–A99, Fig. 3B–B99 and Fig. S3) and an increased mitotic
index evidenced in Cerl22/2 embryos (Fig. 3C), being this result
from the quantification of the proliferating cardiomyocytes present
in the compact myocardium through 9 random fields/ventricle
under 63X magnification (n = 4–5 per genotype). No difference in
mitotic index was observed in the compact RV myocardium at this
stage.
After the compaction process, a natural reduction of the cardiac
cell cycle occurs [43]. In Cerl2 null mutants at E15–15.25, no
statistically significant difference was found in the compact
myocardium in any of the ventricles, despite the tendency to
maintain an increased mitotic index (Fig. 3D). Continuing the time
course investigation on myocardial growth, we analyzed neonates
within few hours of birth (P0) to ensure that we would evaluate
essentially single nucleated cells, before the second peak of DNA
synthesis that leads to the formation of bi-nucleated ventricular
cardiomyocytes (P3–P4) [44]. We sub-divided the myocardium
into AW, LW and PW to define the pattern of proliferation in each
ventricular wall. The results showed a significantly higher
proliferation index in all LV walls of Cerl22/2 (Fig. 3E).
Unexpectedly, we found a high variability of the mitotic index
in the IVS. According to literature, the proliferation capacity of
the IVS decreases upon the completion of the septation process
and, from midgestation onwards, it is mostly the LV myocardial
population that contributes to IVS formation [45]. Therefore, it is
likely that the increased thickness found in IVS in Cerl2 mutants is
due to a substantial influence from the LV. Although we observed
an increased mitotic index in the RVAW and RVLW (Fig. 3E),
this event was not able to induce marked increased on myocardial
thickness. The distinct cell-lineage sources, roles and workloads
between the ventricles may explain the intrinsic capacity of the LV
to be enlarged [46].
Figure 4. Relative mRNA expression levels of cardiac genes is
altered in Cerl22/2 hearts. qRT-PCR was performed in triplicate for
Gata-4, Nkx2.5, a-Mhc, c-Tnt, Anp, Bnp and Ankrd1. Note the altered
expression of cardiac genes during the development in absence of
Cerl2 (A) E13, n = 4. (B) E15–15.25, n = 4 and (C) P0, n = 5. * P,0.05, **
P,0.01 and *** P,0.001.
doi:10.1371/journal.pone.0102716.g004
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To investigate whether the increased mitosis occurs in response
to stimuli from increased cardiac cell death, we observed the
apoptotic cells in Cerl22/2 neonatal mice using the anti-cleaved
Caspase-3 in order to compare the levels of apoptosis in Cerl22/2
neonatal hearts with WT. We did not find alterations in any sub-
region of the LV or IVS (data not shown). These results indicate
that the general increase of the mitotic index observed in the
compact layer of the Cerl22/2 mutant is not related with
alterations in the levels of cellular death.
Besides the hyperplasic cardiac phenotype found in Cerl22/2
neonates, we also investigated whether hypertrophy was also
involved in thickened LV walls and IVS. For that we evaluated the
relative cardiomyocyte area of the AW and PW of the LV and of
the IVS through co-immunostaining using MF20 and laminin as
markers of cardiomyocyte and cardiomyocyte membranes,
respectively (Fig. S1). Our analysis revealed no differences between
the genotypes, suggesting that Cerl22/2 neonatal hearts do not
display hypertrophy at the cellular level. Additionally, cardiac
fibrosis is a classical feature of hypertrophy and cell death [47] and
no evidence of fibrosis in Cerl22/2 neonatal hearts was revealed
through Masson Trichrome staining (Fig. S2). Collectively, these
data demonstrates that in Cerl22/2 the increased myocardial
thickness seen mainly in the LV is caused by cardiomyocyte
hyperplasia and not by hypertrophy (Fig. 3F).
The expression of cardiac genes is affected in Cerl22/2
mice
To evaluate whether the absence of Cerl2 affects the expression
level of cardiac genes from midgestation onward, we performed
qRT-PCR analysis of transcripts isolated from hearts at E13–
E13.25, E15–E15.25 and P0. We analyzed the expression of
transcription factors that are important for normal heart
development such as Gata-4 and Nkx2.5 [3]. We also analyzed
structural genes involved in contractility like a-Mhc and cTnT,
which are activated by the transcription factors Gata-4 and Mef2
[48]. In addition, genes such as Anp, Bnp and Ankrd1, which are
known to be involved in the hypertrophy program and cardiac
stress [49,50] were evaluated. qRT-PCR analysis showed a
dramatic reduction of Gata-4 expression and a slight decrease of
c-TNT in Cer-22/2 hearts at E13 (Fig. 4A). In contrast, we
detected an increase in Nkx2.5 expression levels, and at E15 we
observed a decreased Nkx2.5 expression level. Since alterations in
this gene are associated with conduction abnormalities [51], we
speculate that Cerl22/2 may have impaired cardiac function
already during fetal development. Concurrently, we also detected
reduction of the encoding contractile genes a-Mhc and cTnT but
not altered Gata-4 in Cerl22/2 (Fig. 4B) at this stage. According
with other studies, the alterations of transcription factors such as
Gata-4, Nkx2-5 and Mef2 and their target genes may compromise
the cardiomyocyte differentiation program [48,52]. Therefore, we
believed that the cardiac function of the null mutants might
already be affected during embryogenesis. However, at E13 and
E15 we did not detect any alteration of Anp and Bnp expression in
Cerl22/2 mutants, which indicates that the blood pressure and
blood volume regulating the hypertrophic response in embryonic
stages are not de-regulated [49].
In Cerl22/2 neonatal hearts, we have however detected a
substantial increase of Bnp and Ankrd1 expression (Fig. 4C),
suggesting early cardiac stress in neonates. It has been recently
demonstrated that Ankrd1 is involved in the proliferation of
cardiomyocytes and cardiomyopathy in humans [50,53]. There-
Figure 5. The increased expression level of Ccnd1 suggests the regulatory role of Cerl2 during cardiogenesis. (A) mRNA Cerl2 levels
were normalized to reference genes and compared with WT expression at E8.25–8.5. At E8.25–8.5, pool of two litters (whole embryos, n = 6 each);
E10.5, pool of one litter (isolated hearts n = 6); E13, E15 and P0 isolated hearts (n = 5); E13 pool of two microdissected left and right ventricles (n = 3).
The chart reveals the expression level of Cerl2 until midgestation and in isolated ventricles, Cerl2 is more expressed in the LV. (B) Ccnd1 and Ccnd2
relative expression level in isolated ventricles at E13. qRT-PCR was performed in triplicate. LV and RV indicate left and right ventricles, respectively. *
P,0.05 and ** P,0.01.
doi:10.1371/journal.pone.0102716.g005
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fore, the increased Ankrd1 expression may be associated with the
ventricular hyperplasia found in Cerl22/2 neonates. However, no
significant alteration was found for other cardiac genes (Gata-4,
Nkx2.5, a-Mhc, c-Tnt and ANP) at this stage. Collectively, the
observed changes in the expression levels of essential genes for
cardiogenesis indicate a de-regulation of the cardiac genetic
program in Cerl2 mutant embryos, which consequently compro-
mises the cardiac function and survival of these animals.
The regulatory role of Cerl2 in the cardiomyocyte cell
cycle machinery leads to increased expression of Cyclin
type D1 in Cerl22/2 embryonic hearts
Previous work have shown the expression of Cerl2 in the mouse
node and its function in the initiation of the symmetry breaking
[21,22]. To combine the cardiac phenotype in Cerl2 null mutants
with the putative cardiac function of Cerl2, we evaluated its
expression level during cardiac formation through qRT-PCR
analysis using isolated embryonic, fetal and neonatal mouse hearts.
We used WT embryos at node stage (E8.25–8.5) and Cerl22/2
embryonic hearts as positive and negative controls, respectively.
Relative Cerl2 mRNA expression was found in isolated hearts at
E10.5 and E13 although seemingly lower than the expression in
node stage embryos (Fig. 5A). In addition, we could not detect
Cerl2 expression in the heart beyond midgestation stages (E13). We
then microdissected the LV and RV at E13 in order to assess the
levels of Cerl2 expression in each ventricle, and we have found
more expression in the LV than in the RV (Fig. 5A). As expected,
we did not detect Cerl2 expression in Cerl22/2 hearts (data not
shown). These results suggest that Cerl2 might have an important
role during early cardiogenesis, mainly in the LV myocardium
formation.
In order to investigate the master regulators of G1/S phase
[13,16], we quantified the relative mRNA expression of type D
Cyclins (Ccnd1 and Ccnd2) in isolated ventricles. Despite the similar
expression levels of Ccnd2 in both genotypes, our data uncovered
an increase of Ccnd1 mainly in the LV of Cerl22/2 at E13 (Fig. 5B)
suggesting that the cardiac hyperplasia in the embryonic mutant
hearts is due to overexpression of Ccnd1 in the LV. These results
are consistent with the cardiac phenotype found in Cerl22/2.
Moreover, we conclude that Cerl2 may play a specific mediator
role during cardiomyogenesis, and therefore in its absence, the
marked ventricular hyperplasia is observed predominantly in the
LV.
Absence of Cerl2 leads to increased phosphorylated
Smad2 signaling and up-regulation of Baf60c in
embryonic hearts
Binding of TGFbs/Nodal/Activin to its receptors leads to
phosphorylation of the intracellular proteins known as receptor-
regulated Smads (Smad2 and Smad3) [59]. Then the phosphor-
ylated (p) Smad2/3 interact with the co-factor Smad4 forming a
transcriptional complex, which will translocate to the nucleus to
Figure 6. pSmad2 levels are increased in Cerl22/2 embryonic and neonatal hearts. (A) Western blot at E13 (WT, n = 4 and Cerl22/2 n= 5,
upper) and P0 (n = 4, bottom). (B) Quantitative analysis of anti-pSmad2 normalized with anti-Tubulin at E13 on the left and P0 on the right,
respectively. (C) Immuno-labeled of pSmad2 in left ventricular compact layer at E13. The cardiomyocyte cells (green, labeled with MF20) were co-
labeled with phosphorylated Smad2 (red). The nuclei were stained with DAPI (100X). (D) Quantitative analysis of pSmad2 immuno-labeled in the LV
and RV (arbitrary units) (n = 3). a. u., arbitrary units; LV and RV indicate left and right ventricles, respectively. * P,0.05 and **** P,0.0001.
doi:10.1371/journal.pone.0102716.g006
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regulate the downstream TGFbs/Nodal target genes [60]. Since
Cerl2 is a TGFbs/Nodal antagonist, we postulated that the
absence of Cerl2 might cause alteration in levels of TGFbs/Nodal-
signaling. Therefore, we evaluated the phosphorylation status of
Smad2 (pSmad2) in protein extracts from embryonic (E13) and
neonatal (P0) hearts. The quantification of pSmad2 by Western
blot revealed increased pSmad2 in Cerl22/2 embryonic (E13)
(Fig. 6A, upper and 6B, left) and neonatal hearts (Fig. 6A, bottom
and 6B, right), suggesting an increased transcriptional activity of
TGFbs/Nodal-signaling. Here, we propose two hypotheses that
might explain the elevated phosphorylation of Smad2 found in
Cerl22/2 neonatal hearts. First, the autoregulatory loops are
common in this type of signaling, making it possible that the
absence of Cerl2 at earlier stages allows the prolongation of
TGFbs/Nodal-signaling until later stages; and second, Cerl2 may
interact with other protein(s) that could extend that signaling
activation in the early neonatal period.
We also quantified the level pSmad2 on each ventricular
compact myocardium of the Cerl22/2 embryos at E13 by
quantitative immunofluorescence analysis (Fig. 6C and 6D) and
this analysis showed that the pSmad2 levels on both ventricles are
higher than the control. Interestingly, the bimodal role of the
TGFbs/Nodal-signaling has been reported in the regulation of
cardiogenesis [61]. First, through mesodermal and endodermal
induction to promote cardiac induction and later, to control
cardiomyocyte differentiation [61,62,63].
Work from various laboratories has demonstrated the role of the
ATP-dependent SWItch/Sucrose NonFermentable (SWI/SNF)
chromatin-remodeling complexes in modulating the transcription
of target genes. The SWI/SNF complex is composed by different
members such as Brahma related gene 1 (Brg1) or Brahma (Brm)-
associated factors (BAF) [54]. One of them is Smarcd3 that encodes
the BAF subunit, Baf60c. This epigenetic gene has a fundamental
role during cardiogenesis, acting as a mediator between SWI/SNF
chromatin remodeling complex and cardiac transcription factors
[55]. Moreover, Baf60c RNAi knockdown embryos present severe
heart defects, reduced myocardial proliferation in the ventricles
and altered expression of cardiac markers, causing lethality at
E10–11 [56]. Interestingly, it was reported that another member
of Cerberus family, Cerl1 acts as an early but not as a later cardiac
inductor in Xenopus and in chicken [26,27]. Moreover, Cerl1 has
been described to be in the same regulatory network as Baf60c in
mouse embryonic stem cells (mESC) cardiogenesis [28,29]. All this
prompted us to analyze whether the absence of Cerl2 signals alters
the levels of Baf60c during cardiogenesis in vivo. We evaluated
Baf60c mRNA and protein expression in whole hearts at E13 and
P0 (Fig. 7A–C). Unexpectedly, we found increased mRNA and
protein expression levels of Baf60c in Cerl22/2 hearts at E13.
Since the SWI/SNF chromatin remodeling complex is involved in
controlling cellular proliferation [57] and the overexpression of
Baf60c stimulates the proliferation of neural progenitor cells [58],
the increase of Baf60c expression seems to be consistent with the
ventricular hyperplasia phenotype found in the Cerl2 null mutants
at E13. However in latter midgestation stages Cerl2 was not
detected and therefore in neonatal hearts inactivation of Cerl2 is
not relevant to sustain the increased Baf60c levels. In conclusion,
we postulate that the main involvement of Cerl2 in cardiomyocyte
proliferation occurs during embryonic stages.
Nevertheless in mESC knockdown of Cer1 decreased Baf60c
mRNA and protein levels, through regulation of TGFbs signals
[28] very early in cardiogenesis, suggesting a different role for
these two Cerberus molecules in cardiogenic events that may be
related to their different domains of expression during heart
development.
Although some detailed studies need to be addressed in order to
access the interplay between Cerl2 and the SWI/SNF complex,
our findings contribute to unveil the key role of Cerberus family
during heart development in the mouse.
Here, we provide evidence that an increase in the TGFbs/
Nodal-signaling levels may be responsible for the cardiac
ventricular phenotype in Cerl22/2 hearts. Moreover, this increase
of TGFbs/Nodal-signaling in vivo is associated with a concomitant
increase in Baf60c levels.
Figure 7. The absence of Cerl2 in embryonic hearts leads to up-
regulation of Baf60c. (A) qRT-PCR was performed in triplicate for
Baf60c at E13 (WT, n = 4 and Cerl22/2, n = 3) and P0 (WT, n = 4 and
Cerl22/2, n = 5). (B) Western blot at E13 and P0 (n = 3) and (C)
Quantitative analysis of anti-Baf60c normalized with anti-Tubulin. Note
that no signal of Baf60c was detected in two out of three WT samples at
E13, which precluded the statistical analysis. a. u., arbitrary units. * P,
0.05 and ** P,0.01.
doi:10.1371/journal.pone.0102716.g007
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Conclusion
In conclusion, our study provides the first evidence of the role of
Cerl2 during cardiac development independent of its function in
establishment of the L/R asymmetry. This study reveals an
important breakthrough in the function of Cerl2 to control growth
factor activity in cardiogenesis. We demonstrate that absence of
Cerl2 leads to ectopic TGFbs/Nodal- signaling in the heart leading
to a massive increase of cardiac walls possibly mediated by the
SWI/SNF-like BAF complex. In the future, a tissue-specific
cardiac deletion of Cerl2 would be relevant to determine its precise
contribution during the heart formation.
Supporting Information
Figure S1 Relative cardiomyocyte area in Cerl22/2
neonatal hearts. (A) Represents the LVAW labeling with anti-
laminin (green), 63X. (B) Relative cardiomyocyte area was
measured in 100 cells (mm2), n = 3. LVAW, left ventricle anterior
wall, LVPW, left ventricle posterior wall and IVS, interventricular
septum. * P,0.05.
(TIF)
Figure S2 No fibrosis was detected in Cerl22/2 neo-
nates. Masson-trichrome staining did not reveal fibrosis in Cerl2
mutants (20X).
(TIF)
Figure S3 Cerl22/2 animals display increased pH3
immunoreactivity in the left ventricle. (A and B) Corre-
spond to merged images at E13 of MF20 (green), pH3 (red) and
DAPI (blue). (A9 and B9) MF20 and pH3; (A99 and B99) pH3 and
DAPI. (A999 and B999) pH3. LV, left ventricle (10X). Scale bar:
100 mm.
(TIF)
Table S1 Antibodies used in this study.
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